These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 39118052)

  • 21. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Molina KC; Peers JL; Russell S; Wynia MK; Ginde AA
    Int J Infect Dis; 2023 Mar; 128():310-317. PubMed ID: 36229005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world evaluation of bebtelovimab effectiveness during the period of COVID-19 Omicron variants, including BA.4/BA.5.
    Molina KC; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    Int J Infect Dis; 2023 Jul; 132():34-39. PubMed ID: 37072054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status and clinical outcomes of pharmacotherapies according to SARS-CoV-2 mutations in patients with mild-to-moderate COVID-19: a retrospective single center study.
    Park S; Je NK; Kim DW; Park M; Heo J
    BMC Infect Dis; 2024 Sep; 24(1):871. PubMed ID: 39223456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment.
    Chang MC; Wu PF; Ho YC; Lin WY; Wu CY; Liu SY; Liu CJ; Lin YT
    J Infect Public Health; 2024 Jul; 17(7):102460. PubMed ID: 38820894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases.
    Suzuki A; Fukumitsu K; Fukihara J; Katano T; Kako H; Maeda Y; Ishii M; Niimi A; Imaizumi K; Yamaguchi E
    J Chemother; 2024 Apr; 36(2):127-132. PubMed ID: 38044564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
    Antinori S; Cossu MV; Ridolfo AL; Rech R; Bonazzetti C; Pagani G; Gubertini G; Coen M; Magni C; Castelli A; Borghi B; Colombo R; Giorgi R; Angeli E; Mileto D; Milazzo L; Vimercati S; Pellicciotta M; Corbellino M; Torre A; Rusconi S; Oreni L; Gismondo MR; Giacomelli A; Meroni L; Rizzardini G; Galli M
    Pharmacol Res; 2020 Aug; 158():104899. PubMed ID: 32407959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.
    Med Lett Drugs Ther; 2022 Feb; 64(1644):31-32. PubMed ID: 35171898
    [No Abstract]   [Full Text] [Related]  

  • 33. Update on efficacy of the approved remdesivir regimen for treatment of COVID-19: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.
    Okoli GN; Reddy VK; Lam OL; Askin N; Rabbani R
    Curr Med Res Opin; 2024 Aug; 40(8):1277-1287. PubMed ID: 38850519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
    Odeti S; Yellepeddi VK
    Am Fam Physician; 2021 Sep; 104(3):311-312. PubMed ID: 34523893
    [No Abstract]   [Full Text] [Related]  

  • 35. Association of renal function with mortality among hospitalized patients treated with remdesivir for COVID-19.
    Gonzalez Suarez ML; Mara KC; Rivera CG; Chesdachai S; Draper E; Razonable RR
    PLoS One; 2024; 19(6):e0303896. PubMed ID: 38875257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital.
    Hidalgo-Tenorio C; García-Vallecillos C; Sequera-Arquelladas S;
    Medicine (Baltimore); 2021 Sep; 100(37):e27228. PubMed ID: 34664862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
    Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
    PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
    Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
    Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study.
    Mazzitelli M; Trunfio M; Sasset L; Scaglione V; Ferrari A; Mengato D; Gardin S; Bonadiman N; Calandrino L; Agostini E; Cattelan AM
    J Med Virol; 2023 Mar; 95(3):e28660. PubMed ID: 36905216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.